{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T06:50:32Z","timestamp":1780642232558,"version":"3.54.1"},"reference-count":28,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2016,5,5]],"date-time":"2016-05-05T00:00:00Z","timestamp":1462406400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"name":"Royal Marsden National Health Service Foundation Trust"},{"DOI":"10.13039\/501100000027","name":"Institute of Cancer Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000027","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Cancer Research U.K. Scientific Executive Board\u2013Centre Award","award":["C347\/A15403"],"award-info":[{"award-number":["C347\/A15403"]}]},{"name":"Cancer Research U.K. Quinquennial Award"},{"name":"Cancer Therapeutics Unit","award":["C309\/A11566"],"award-info":[{"award-number":["C309\/A11566"]}]},{"name":"Experimental Cancer Medicine Centre Network","award":["C12540\/A15573"],"award-info":[{"award-number":["C12540\/A15573"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016,7,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background.<\/jats:title>\n                  <jats:p>Dysregulation of the phosphatidylinositol 3-kinase\/protein kinase B\/mammalian target of rapamycin (PI3K\/AKT\/mTOR) pathway is implicated in human cancer growth and progression. Agents targeting this pathway are associated with hyperglycemia due to interaction with the insulin-glucose regulatory axis. Identifying the predictive factors for hyperglycemia in patients treated with these agents may help direct future management.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Materials and Methods.<\/jats:title>\n                  <jats:p>Clinical characteristics and outcomes of patients treated consecutively with PI3K, AKT, or mTOR inhibitors in the Drug Development Unit, The Royal Marsden (RM) National Health Service (NHS) Foundation Trust, between 2007 and 2012 were recorded. Baseline variables and their association with grade 3 hyperglycemia (Common Terminology Criteria for Adverse Events, version 3.0) were analyzed by using the chi-square test and Fisher exact test for categorical variables and binary logistic regression for continuous variables.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results.<\/jats:title>\n                  <jats:p>A total of 341 patients were treated in 12 phase I trials of PI3K\/AKT\/mTOR inhibitors, and 298 patients (87.4%) developed hyperglycemia. Hyperglycemia was grade 1 in 217 (72.8%) and grade 2 in 61 (20.5%) patients, respectively. Grade \u22653 hyperglycemia was seen in 6.7% of patients (n = 20). According to the chi-square test, age &amp;lt;65 years (p = .03), history of diabetes (p = .003), and treatment with AKT and dual PI3K\/mTOR inhibitors (p &amp;lt; .0005) predicted the occurrence of grade 3 hyperglycemia. Of 24 patients requiring intervention, 20 received metformin, 2 dietary advice, 1 insulin, and 1 both metformin and insulin. One patient required dose reduction. There were no permanent drug discontinuations, and no hyperglycemia-related dose-limiting toxicities were observed; thus, the recommended phase II dose was not affected by the hyperglycemia observed in our cohort.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion.<\/jats:title>\n                  <jats:p>Hyperglycemia is common in patients treated with PI3K\/AKT\/mTOR inhibitors; however, it is manageable with conventional treatment. Predictive factors of age, history of diabetes, and administration of AKT and dual PI3K\/mTOR inhibitors warrant prospective validation.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1634\/theoncologist.2015-0248","type":"journal-article","created":{"date-parts":[[2016,5,6]],"date-time":"2016-05-06T00:45:16Z","timestamp":1462495516000},"page":"855-860","source":"Crossref","is-referenced-by-count":58,"title":["Hyperglycemia and Phosphatidylinositol 3-Kinase\/Protein Kinase B\/Mammalian Target of Rapamycin (PI3K\/AKT\/mTOR) Inhibitors in Phase I Trials: Incidence, Predictive Factors, and Management"],"prefix":"10.1093","volume":"21","author":[{"given":"Khurum H.","family":"Khan","sequence":"first","affiliation":[{"name":"Drug Development Unit, The Royal Marsden (RM) National Health Service (NHS) Foundation Trust, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mabel","family":"Wong","sequence":"additional","affiliation":[{"name":"Drug Development Unit, The Royal Marsden (RM) National Health Service (NHS) Foundation Trust, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karim","family":"Rihawi","sequence":"additional","affiliation":[{"name":"Drug Development Unit, The Royal Marsden (RM) National Health Service (NHS) Foundation Trust, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shankar","family":"Bodla","sequence":"additional","affiliation":[{"name":"Department of Statistics, The Royal Marsden (RM) National Health Service (NHS) Foundation Trust, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Morganstein","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, The Royal Marsden (RM) National Health Service (NHS) Foundation Trust, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Udai","family":"Banerji","sequence":"additional","affiliation":[{"name":"Drug Development Unit, The Royal Marsden (RM) National Health Service (NHS) Foundation Trust, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lulama R.","family":"Molife","sequence":"additional","affiliation":[{"name":"Drug Development Unit, The Royal Marsden (RM) National Health Service (NHS) Foundation Trust, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2016,5,5]]},"reference":[{"key":"2021122309525370300_B1","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1038\/nrc839","article-title":"The phosphatidylinositol 3-Kinase AKT pathway in human cancer","volume":"2","author":"Vivanco","year":"2002","journal-title":"Nat Rev Cancer"},{"key":"2021122309525370300_B2","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1038\/nrc2664","article-title":"Targeting PI3K signalling in cancer: Opportunities, challenges and limitations","volume":"9","author":"Engelman","year":"2009","journal-title":"Nat Rev Cancer"},{"key":"2021122309525370300_B3","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/S1043-2760(02)00662-8","article-title":"Role of Akt\/protein kinase B in metabolism","volume":"13","author":"Whiteman","year":"2002","journal-title":"Trends Endocrinol Metab"},{"key":"2021122309525370300_B4","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1248\/bpb.30.1610","article-title":"Role of phosphatidylinositol 3-kinase activation on insulin action and its alteration in diabetic conditions","volume":"30","author":"Asano","year":"2007","journal-title":"Biol Pharm Bull"},{"key":"2021122309525370300_B5","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1091\/mbc.e10-08-0665","article-title":"A Ral GAP complex links PI 3-kinase\/Akt signaling to RalA activation in insulin action","volume":"22","author":"Chen","year":"2011","journal-title":"Mol Biol Cell"},{"key":"2021122309525370300_B6","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1146\/annurev.physiol.68.040104.124723","article-title":"From mice to men: Insights into the insulin resistance syndromes","volume":"68","author":"Biddinger","year":"2006","journal-title":"Annu Rev Physiol"},{"key":"2021122309525370300_B7","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1126\/science.292.5522.1728","article-title":"Insulin resistance and a diabetes mellitus-like syndrome in mice lacking the protein kinase Akt2 (PKB beta)","volume":"292","author":"Cho","year":"2001","journal-title":"Science"},{"key":"2021122309525370300_B8","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1126\/science.1096706","article-title":"A family with severe insulin resistance and diabetes due to a mutation in AKT2","volume":"304","author":"George","year":"2004","journal-title":"Science"},{"key":"2021122309525370300_B9","doi-asserted-by":"crossref","first-page":"253","DOI":"10.5732\/cjc.013.10057","article-title":"Targeting the PI3K-AKT-mTOR signaling network in cancer","volume":"32","author":"Khan","year":"2013","journal-title":"Chin J Cancer"},{"key":"2021122309525370300_B10","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/S0140-6736(08)61039-9","article-title":"Efficacy of everolimus in advanced renal cell carcinoma: A double-blind, randomised, placebo-controlled phase III trial","volume":"372","author":"Motzer","year":"2008","journal-title":"Lancet"},{"key":"2021122309525370300_B11","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1056\/NEJMoa066838","article-title":"Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma","volume":"356","author":"Hudes","year":"2007","journal-title":"N Engl J Med"},{"key":"2021122309525370300_B12","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1056\/NEJMoa1109653","article-title":"Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer","volume":"366","author":"Baselga","year":"2012","journal-title":"N Engl J Med"},{"key":"2021122309525370300_B13","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1056\/NEJMoa1009290","article-title":"Everolimus for advanced pancreatic neuroendocrine tumors","volume":"364","author":"Yao","year":"2011","journal-title":"N Engl J Med"},{"key":"2021122309525370300_B14","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1200\/JCO.2007.14.5482","article-title":"Dose- and schedule-dependent inhibition of the mammalian target of rapamycin pathway with everolimus: A phase I tumor pharmacodynamic study in patients with advanced solid tumors","volume":"26","author":"Tabernero","year":"2008","journal-title":"J Clin Oncol"},{"key":"2021122309525370300_B15","doi-asserted-by":"crossref","first-page":"530","DOI":"10.18632\/oncotarget.188","article-title":"Targeting the PI3K\/Akt\/mTOR pathway\u2013beyond rapalogs","volume":"1","author":"Markman","year":"2010","journal-title":"Oncotarget"},{"key":"2021122309525370300_B16","doi-asserted-by":"crossref","first-page":"4688","DOI":"10.1200\/JCO.2011.35.5263","article-title":"First-in-man clinical trial of the oral pan-AKT inhibitor MK-2206 in patients with advanced solid tumors","volume":"29","author":"Yap","year":"2011","journal-title":"J Clin Oncol"},{"key":"2021122309525370300_B17","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1158\/1078-0432.CCR-14-2424","article-title":"Higher risk of infections with PI3K-AKT-mTOR pathway inhibitors in patients with advanced solid tumors on phase I clinical trials","volume":"21","author":"Rafii","year":"2015","journal-title":"Clin Cancer Res"},{"key":"2021122309525370300_B18","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1089\/152091501300209633","article-title":"The relation of type 2 diabetes and cancer","volume":"3","author":"Strickler","year":"2001","journal-title":"Diabetes Technol Ther"},{"key":"2021122309525370300_B19","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1111\/bjd.12355","article-title":"Markers of systemic inflammation in psoriasis: A systematic review and meta-analysis","volume":"169","author":"Dowlatshahi","year":"2013","journal-title":"Br J Dermatol"},{"key":"2021122309525370300_B20","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1097\/CEJ.0b013e3283656394","article-title":"Type 2 diabetes mellitus, glycemic control, and cancer risk","volume":"23","author":"Onitilo","year":"2014","journal-title":"Eur J Cancer Prev"},{"key":"2021122309525370300_B21","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/j.nutres.2013.07.019","article-title":"Liver enzymes but not free fatty acid levels predict markers of insulin sensitivity in overweight and obese, nondiabetic adults","volume":"33","author":"Gray","year":"2013","journal-title":"Nutr Res"},{"key":"2021122309525370300_B22","doi-asserted-by":"crossref","first-page":"2775","DOI":"10.1097\/01.ASN.0000141965.28037.EE","article-title":"Obesity-initiated metabolic syndrome and the kidney: A recipe for chronic kidney disease?","volume":"15","author":"Bagby","year":"2004","journal-title":"J Am Soc Nephrol"},{"key":"2021122309525370300_B23","doi-asserted-by":"crossref","first-page":"e74616","DOI":"10.1371\/journal.pone.0074616","article-title":"Increased risk of colorectal cancer in type 2 diabetes is independent of diet quality","volume":"8","author":"Jarvandi","year":"2013","journal-title":"PLoS One"},{"key":"2021122309525370300_B24","doi-asserted-by":"crossref","first-page":"2919","DOI":"10.1200\/JCO.2011.39.7356","article-title":"Management of metabolic effects associated with anticancer agents targeting the PI3K-Akt-mTOR pathway","volume":"30","author":"Busaidy","year":"2012","journal-title":"J Clin Oncol"},{"key":"2021122309525370300_B25","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.cmet.2010.02.002","article-title":"Specific roles of the p110alpha isoform of phosphatidylinsositol 3-kinase in hepatic insulin signaling and metabolic regulation","volume":"11","author":"Sopasakis","year":"2010","journal-title":"Cell Metab"},{"key":"2021122309525370300_B26","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1038\/nature07091","article-title":"Essential roles of PI(3)K-p110beta in cell growth, metabolism and tumorigenesis","volume":"454","author":"Jia","year":"2008","journal-title":"Nature"},{"key":"2021122309525370300_B27","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1158\/1535-7163.MCT-05-0149","article-title":"The phosphatidylinositol-3-kinase inhibitor PX-866 overcomes resistance to the epidermal growth factor receptor inhibitor gefitinib in A-549 human non-small cell lung cancer xenografts","volume":"4","author":"Ihle","year":"2005","journal-title":"Mol Cancer Ther"},{"key":"2021122309525370300_B28","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.cmet.2006.05.003","article-title":"Nutrient overload, insulin resistance, and ribosomal protein S6 kinase 1, S6K1","volume":"3","author":"Um","year":"2006","journal-title":"Cell Metab"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1634\/theoncologist.2015-0248","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1634\/theoncologist.2015-0248","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/21\/7\/855\/41875110\/oncolo_21_7_855.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/21\/7\/855\/41875110\/oncolo_21_7_855.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,24]],"date-time":"2021-12-24T04:21:48Z","timestamp":1640319708000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/21\/7\/855\/6401438"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,5,5]]},"references-count":28,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2016,5,5]]},"published-print":{"date-parts":[[2016,7,1]]}},"URL":"https:\/\/doi.org\/10.1634\/theoncologist.2015-0248","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2016,7,1]]},"published":{"date-parts":[[2016,5,5]]}}}